[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0514553A - composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo

Info

Publication number
BRPI0514553A
BRPI0514553A BRPI0514553-8A BRPI0514553A BRPI0514553A BR PI0514553 A BRPI0514553 A BR PI0514553A BR PI0514553 A BRPI0514553 A BR PI0514553A BR PI0514553 A BRPI0514553 A BR PI0514553A
Authority
BR
Brazil
Prior art keywords
treating
compound
disorder
methods
salt
Prior art date
Application number
BRPI0514553-8A
Other languages
English (en)
Inventor
Don Richard Finley
Terry Patrick Finn
Philip Arthur Hipskind
William Joseph Hornback
Cynthia Darshini Jesudason
Takako Takakuwa
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0514553A publication Critical patent/BRPI0514553A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA INIBIR O RECEPTOR DE HISTAMINA H3 EM UM MAMìFERO, PARA O TRATAMENTO DE UM DISTúRBIO DO SISTEMA NERVOSO, PARA O TRATAMENTO DE OBESIDADE E PARA O TRATAMENTO DE UM DISTúRBIO OU DOENçA, E, USO DE UM COMPOSTO OU UM SAL DO MESMO A presente invenção diz respeito a um novo composto da Fórmula (I) ou um sal farmaceuticamente aceitável do mesmo, tendo atividade antagonista ou agonista inversa do receptor de histamina H3, assim como métodos para preparar tais compostos. Em uma outra forma de realização, a invenção divulga composições farmacêuticas compreendendo compostos da fórmula (I) assim como métodos de usá-los no tratamento da obesidade, deficiências cognitivas, narcolepsia, e outras doenças relacionadas ao receptor de histamina H3.
BRPI0514553-8A 2004-08-23 2005-08-15 composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo BRPI0514553A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60362804P 2004-08-23 2004-08-23
PCT/US2005/029032 WO2006023462A1 (en) 2004-08-23 2005-08-15 Histamine h3 receptor agents, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
BRPI0514553A true BRPI0514553A (pt) 2008-06-17

Family

ID=35385793

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514553-8A BRPI0514553A (pt) 2004-08-23 2005-08-15 composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo

Country Status (10)

Country Link
US (2) US7705025B2 (pt)
EP (1) EP1784400B1 (pt)
JP (1) JP4942654B2 (pt)
CN (1) CN101006082B (pt)
AU (1) AU2005277518B2 (pt)
BR (1) BRPI0514553A (pt)
CA (1) CA2577061C (pt)
ES (1) ES2534605T3 (pt)
MX (1) MX2007002274A (pt)
WO (1) WO2006023462A1 (pt)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008301B2 (en) * 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
KR20070067165A (ko) 2004-10-13 2007-06-27 피티씨 테라퓨틱스, 인크. 넌센스 변이 억제용 화합물, 및 이의 사용 방법
MX2007012110A (es) * 2005-04-01 2007-11-21 Lilly Co Eli Agentes del receptor de histamina h3, preparacion y usos terapeuticos.
AU2007227681A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
WO2007136668A2 (en) 2006-05-19 2007-11-29 Wyeth N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
WO2007143824A1 (en) * 2006-06-13 2007-12-21 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
WO2008053469A2 (en) * 2006-10-29 2008-05-08 Alon Shalev An extra-vascular wrapping for treating aneurysmatic aorta and methods thereof
US20100113776A1 (en) * 2006-12-14 2010-05-06 Taisho Pharmaceutical Co.,Ltd. Pyrazole derivative
AR066721A1 (es) 2007-05-24 2009-09-09 Wyeth Corp Derivados de benzo[d]imidazol-1-il, composicion farmaceutica, proceso de preparacion y uso.
US7803825B2 (en) 2007-07-16 2010-09-28 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
WO2009063953A1 (ja) 2007-11-13 2009-05-22 Taisho Pharmaceutical Co., Ltd. フェニルピラゾール誘導体
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
EP2243777A1 (de) * 2009-04-03 2010-10-27 Bayer CropScience AG Verfahren zum Herstellen von Pyridyl-substituierten Pyrazolen
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
CA2766347C (en) 2009-06-23 2017-04-25 Endospan Ltd. Vascular prostheses for treating aneurysms
WO2011004374A1 (en) 2009-07-09 2011-01-13 Endospan Ltd. Apparatus for closure of a lumen and methods of using the same
DE102009038123A1 (de) 2009-08-17 2011-02-24 Aicuris Gmbh & Co. Kg Substituierte (Thiazolyl-carbonyl)imidazolidinone und ihre Verwendung
WO2011064782A2 (en) 2009-11-30 2011-06-03 Endospan Ltd. Multi-component stent-graft system for implantation in a blood vessel with multiple branches
CA2783554C (en) 2009-12-08 2016-02-16 Endospan Ltd. Endovascular stent-graft system with fenestrated and crossing stent-grafts
US9468517B2 (en) 2010-02-08 2016-10-18 Endospan Ltd. Thermal energy application for prevention and management of endoleaks in stent-grafts
US20110208289A1 (en) * 2010-02-25 2011-08-25 Endospan Ltd. Flexible Stent-Grafts
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AU2011261164A1 (en) * 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
MX343905B (es) 2010-11-03 2016-11-28 Dow Agrosciences Llc Composiciones pesticidas y procesos relacionados a las mismas.
US9526638B2 (en) 2011-02-03 2016-12-27 Endospan Ltd. Implantable medical devices constructed of shape memory material
US9855046B2 (en) 2011-02-17 2018-01-02 Endospan Ltd. Vascular bands and delivery systems therefor
ME02212B (me) 2011-02-23 2016-02-20 Suven Life Sciences Ltd Nova jedinjenja kao ligandi histamin h3 receptora
WO2012117395A1 (en) 2011-03-02 2012-09-07 Endospan Ltd. Reduced-strain extra- vascular ring for treating aortic aneurysm
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US8574287B2 (en) 2011-06-14 2013-11-05 Endospan Ltd. Stents incorporating a plurality of strain-distribution locations
ES2568377T3 (es) 2011-06-21 2016-04-28 Endospan Ltd Sistema endovascular con endoprótesis que solapan circunferencialmente
WO2013005207A1 (en) 2011-07-07 2013-01-10 Endospan Ltd. Stent fixation with reduced plastic deformation
US9839510B2 (en) 2011-08-28 2017-12-12 Endospan Ltd. Stent-grafts with post-deployment variable radial displacement
KR102006039B1 (ko) 2011-10-26 2019-07-31 다우 아그로사이언시즈 엘엘씨 살충 조성물 및 그와 관련된 방법
US9427339B2 (en) 2011-10-30 2016-08-30 Endospan Ltd. Triple-collar stent-graft
US9597204B2 (en) 2011-12-04 2017-03-21 Endospan Ltd. Branched stent-graft system
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
BR112014026526A2 (pt) 2012-04-27 2017-06-27 Dow Agrosciences Llc composições pesticidas e processos relacionados às mesmas
WO2013171730A1 (en) * 2012-05-15 2013-11-21 Endospan Ltd. Stent-graft with fixation elements that are radially confined for delivery
NZ702539A (en) 2012-05-31 2016-11-25 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
PL2888243T3 (pl) 2012-08-23 2017-01-31 Suven Life Sciences Limited Związki akryloamidowe jako ligandy receptora histaminowego H3
US9668892B2 (en) 2013-03-11 2017-06-06 Endospan Ltd. Multi-component stent-graft system for aortic dissections
KR20160074543A (ko) 2013-10-17 2016-06-28 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
US9102654B2 (en) 2013-10-17 2015-08-11 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
MX2016004940A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Proceso para la preparacion de compuestos plaguicidas.
JP2016535010A (ja) 2013-10-17 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
BR112016007518A2 (pt) 2013-10-17 2017-08-01 Dow Agrosciences Llc processos para a preparação de compostos pesticidas
CA2925952A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
MX2016004943A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Procesos para la preparacion de compuestos plaguicidas.
AU2014340416B2 (en) 2013-10-22 2017-09-07 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CA2926433A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
AR098091A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones pesticidas sinérgicas y métodos relacionados
TW201519773A (zh) 2013-10-22 2015-06-01 Dow Agrosciences Llc 協同性殺蟲組成物及相關方法（五）
JP2016535026A (ja) 2013-10-22 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
JP2016535024A (ja) 2013-10-22 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
CN105658062A (zh) 2013-10-22 2016-06-08 美国陶氏益农公司 协同杀虫组合物和相关方法
CA2926345A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CN105828610B (zh) 2013-10-22 2019-07-19 美国陶氏益农公司 杀虫组合物和与其相关的方法
WO2015061170A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CN105828613A (zh) 2013-10-22 2016-08-03 美国陶氏益农公司 协同杀虫组合物和与其相关的方法
CN105828611A (zh) 2013-10-22 2016-08-03 美国陶氏益农公司 协同杀虫组合物和相关方法
JP2016536304A (ja) 2013-10-22 2016-11-24 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
KR102275655B1 (ko) 2013-10-22 2021-07-09 코르테바 애그리사이언스 엘엘씨 살충 조성물 및 관련 방법
RU2667777C2 (ru) 2013-10-22 2018-09-24 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции и связанные с ними способы
AU2014340430B2 (en) 2013-10-22 2017-05-25 Dow Agrosciences Llc Pesticidal compositions and related methods
NZ719749A (en) 2013-10-22 2017-10-27 Dow Agrosciences Llc Pesticidal compositions and related methods
US10603197B2 (en) 2013-11-19 2020-03-31 Endospan Ltd. Stent system with radial-expansion locking
BR112017000565A2 (pt) 2014-07-31 2017-11-07 Dow Agrosciences Llc processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
AR098110A1 (es) 2014-07-31 2016-05-04 Dow Agrosciences Llc Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina
JP2017523163A (ja) 2014-07-31 2017-08-17 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの製造方法
CN107074774A (zh) 2014-08-19 2017-08-18 美国陶氏益农公司 制备3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的方法
WO2016039781A1 (en) 2014-09-12 2016-03-17 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
EP3068339B1 (en) 2014-12-18 2017-11-01 Endospan Ltd. Endovascular stent-graft with fatigue-resistant lateral tube
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN110325036B (zh) 2016-12-29 2021-10-26 美国陶氏益农公司 用于制备杀虫化合物的方法
US10100033B2 (en) 2016-12-29 2018-10-16 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
US5652258A (en) 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
CN1192144A (zh) 1995-05-30 1998-09-02 格里亚特克公司 1h－4(5)－取代的咪唑衍生物
DE69722592D1 (de) 1996-02-09 2003-07-10 Black James Foundation Histamin h 3 rezeptorliganden
CA2441080A1 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
BR0306980A (pt) 2002-02-01 2004-11-09 Novo Nordisk As Composto, uso de um composto, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com o receptor de histamina h3
MEP52808A (en) * 2003-02-26 2011-05-10 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
BRPI0509298A (pt) * 2004-04-01 2007-09-18 Lilly Co Eli composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto

Also Published As

Publication number Publication date
AU2005277518A1 (en) 2006-03-02
WO2006023462A1 (en) 2006-03-02
AU2005277518B2 (en) 2011-08-04
US20100029608A1 (en) 2010-02-04
CN101006082B (zh) 2010-09-29
JP2008510808A (ja) 2008-04-10
EP1784400A1 (en) 2007-05-16
JP4942654B2 (ja) 2012-05-30
MX2007002274A (es) 2007-05-07
CA2577061C (en) 2014-02-18
US7705025B2 (en) 2010-04-27
EP1784400B1 (en) 2015-01-14
CN101006082A (zh) 2007-07-25
CA2577061A1 (en) 2006-03-02
US20090048225A1 (en) 2009-02-19
ES2534605T3 (es) 2015-04-24

Similar Documents

Publication Publication Date Title
BRPI0514553A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo
BRPI0509298A (pt) composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
BRPI0812504B8 (pt) composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
BRPI0508461A (pt) diaminopirimidinas como antagonistas de p2x3 e p2x2/3
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung
CY1110453T1 (el) Αναστολεις υποδοχεα η3 ισταμινης, παρασκευη και θεραπευτικες χρησεις
BRPI0511642A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor h3 da histamina em um mamìfero, para tratamento ou prevenção de um distúrbio do sistema nervoso ou outro distúrbio associado com o receptor h3 da histamina, para tratamento ou prevenção da obesidade, para tratamento ou prevenção de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]